PHGE (BiomX) חוב לטווח קצר להון

BiomX Inc. develops targeted bacteriophage-based drugs, leveraging strategic partnerships with global pharma behemoths to accelerate research. Demand for such solutions remains decoupled from market cycles due to the global crisis of antibiotic resistance. This chart of the company's price action on GURU.Markets reflects the 0.30 metric, while the business actively completes Phase II trials for new medications.

Optimizing the capital structure allows for the separation of fundamental business value from speculative risks, which is critical for BiomX Inc. (PHGE) given its high scientific authority in phage therapy. By analyzing the short-term debt-to-equity ratio, an investor assesses the proportion of liabilities due within one year relative to equity, where a decreasing coefficient confirms financial stability and protection against bankruptcy.